, as well as data from studies carried out once the vaccine was deployed during the 2022 mpox outbreak. More than 1.2 million people in the United States received at least one dose of the vaccine at that time, and studies showed it provided a high level of protection against mpox.
Yet the W.H.O. did not open formal consideration of that research until last week.
Deusdedit Mubangizi, the W.H.O.’s director of health product policy and standards, said that the organization’s group of experts would meet the week of Sept. 16 to consider the submitted data, and could issue a license as early as that week if they were satisfied.
I wonder what the racial makeup of that group of experts is, or how they would react if the virus was spreading in a community that included their families. Or what is the racial makeup of the people funding this whole organization and deciding what is and isn’t some kind of “quicker than 2 years timeframe” emergency situation.
I stand by my assessment
Deusdedit Mubangizi isn’t exactly a white guy.
I wonder what the racial makeup of that group of experts is, or how they would react if the virus was spreading in a community that included their families. Or what is the racial makeup of the people funding this whole organization and deciding what is and isn’t some kind of “quicker than 2 years timeframe” emergency situation.